No visual complaints. The patient has been followed every 3 months.
Color vision remains normal.
Fundus appearance shows mild macular pigment mottling, unchanged from July, 1999. A Fluorescein angiogram was performed to enhance visibility of the pigment alterations. Primarily used by rheumatologists for the treatment of rheumatoid arthritis and systemic lupus erythematosus. Forms strong bonds with melanin in the retinal pigment epithelium. This binding results in an accumulation of the drug in the retina, leading to toxicity.